Kudos to @oncologybg.bsky.social on a top 10 interactive post! We are excited to have cancer researchers with global reach working here @sinclaircri.bsky.social & using multiple platforms to build worldwide communications. #LARVOL #ELCC2026
@queensuhealth.bsky.social @queensuresearch.bsky.social

Dr Girard on Updated Data From the PALOMA-2 Trial in EGFR-Mutant NSCLC | OncLive Nicolas Girard, MD, PhD, discusses updated data from the phase 2 PALOMA-2 trial (NCT05498428) that were presented at the 2026 European Lung Cancer Congress.

WATCH: Nicolas Girard, MD, PhD, of @institutcurie.bsky.social discusses updated data from the phase 2 PALOMA-2 trial that were presented at the 2026 European Lung Cancer Congress. #ELCC26 #ELCC2026 #lcsm #lungcancer
www.onclive.com/view/dr-gira...

🕐 more about #time-of-day and ICI
📋 IPD meta-analysis across 8 Roche/atezolizumab RCTs (n=3,060 #lung cancer pts). First 2 ICI cycles administered before vs. after 12:00 pm
🎯 OS HR late vs early: 1.039 (95% CI 0.925–1.168)
→ Upper limit < 1.18: non-inferiority demonstrated ✅
#ELCC2026

Setidegrasib Is Safe and Active in KRAS G12D-Mutated NSCLC | OncLive Setidegrasib yielded antitumor activity with a tolerable safety profile in KRAS G12D-mutated NSCLC.

Setidegrasib yielded antitumor activity with a tolerable safety profile in KRAS G12D-mutated NSCLC. @myesmo.bsky.social #ELCC26 #ELCC2026 #lcsm #oncology
www.onclive.com/view/setideg...

Osimertinib Plus Chemotherapy Doubles PFS in EGFR-, TP53-Mutant Advanced NSCLC | OncLive Osimertinib plus chemotherapy prolonged PFS vs osimertinib alone in patients with advanced NSCLC harboring concurrent EGFR and TP53 mutations.

Osimertinib plus chemotherapy prolonged PFS vs osimertinib alone in patients with advanced NSCLC harboring concurrent EGFR and TP53 mutations.
@myesmo.bsky.social
#ELCC26 #ELCC2026 #lcsm #oncology
www.onclive.com/view/osimert...

First-Line Serplulimab Plus Iza-Bren Is Deemed Tolerable and Has Antitumor Activity in ES-SCLC | OncLive Frontline iza-bren in combination with serplulimab was associated with a tolerable and manageable safety profile and elicited responses in ES-SCLC.

Frontline iza-bren in combination with serplulimab was associated with a tolerable and manageable safety profile and elicited responses in ES-SCLC. @myesmo.bsky.social #ELCC26 #ELCC2026 #lcsm #oncology
www.onclive.com/view/first-l...

Ahead of ELCC 2026, we spoke with expert lung cancer clinicians to gain their insights into the most anticipated abstracts that will be presented at the meeting.
🔒 Sign up here to read: www.onclive.com/view/thoraci...
#oncology #ELCC2026 #lungcancer #NSCLC #lcsm

🚨 Coming Soon! 🚨

Prof. Nicolas Girard is joining us at #ELCC2026, to review the latest data on oncogene-addicted #NSCLC

Make sure you FOLLOW us to see his update! 🎬

🤝Endorsed by @lungcancereurope.bsky.social

Supported by an Independent Educational Grant from Bayer

#MedicalEducation #MedSky